Heumann, Thatcher http://orcid.org/0000-0003-2606-3379
Azad, Nilofer http://orcid.org/0000-0002-9613-3988
Article History
Received: 2 June 2021
Accepted: 26 July 2021
First Online: 30 September 2021
Change Date: 19 October 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s10555-021-09999-7
Declarations
:
: Dr. Heumann has no conflict of interests. Dr. Azad receives research funding from BMS, Merck, Incyte, Syndax, Intensity, Bayer, EMD Serono. She receives financial compensation as a consultant for AstraZeneca and Merck/EMD Serono.